GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                               
                            
                                
                                                                Synonyms: Example 6 [WO2014169843]
                                 
                                                         
                            
                            
                            
                                 
                                
                                luvometinib is an approved drug 
                                                        
                                                    
                                Compound class: 
                                                            Synthetic organic
                                 
                                
                                    
                                        Comment: The chemical structure for luvometinib was obtained from WHO proposed INN list 131 (August 2024). The INN document records luvometinib as a mitogen-activated protein kinase (MEK) inhibitor and antineoplastic agent. It is one of the compounds claimed in patent WO2014169843A1 (Fochon Pharmaceutical) [4]. Fochon Pharmaceutical have one MEK inhibitor in their declared development pipeline, FCN-159. Published information about FCN-159 indicates that it is an orally available MEK1/2 inhibitor lead for the treament of BRAF- or RAS-driven tumours [2-3]. Inhibition of MEK1/2 disrupts downstream MAPK signalling that is activated by upstream mutant RAF/RAS enzymes in malignancies.
                                    
                                 
                            
                            
                          
                                
                                    
                                
                          
                                   
                                   
                                  
                                    
                                    
                                     | 
                                    
                                        
                                         
  | 
                                    
                                
                                |||||||||||||||||||||||||||||||||||
Classification ![]()  | 
                                                    |
| Compound class | Synthetic organic | 
| Approved drug? | Yes. China NMPA (2025) | 
IUPAC Name ![]()  | 
                                                        
| N-[3-[6-cyclopropyl-3-fluoro-4-(2-fluoro-4-iodoanilino)-1-methyl-2,5-dioxopyrido[2,3-d]pyridazin-8-yl]phenyl]cyclopropanesulfonamide | 
International Nonproprietary Names ![]()  | 
                                                        |
| INN number | INN | 
| 13248 | luvometinib | 
Synonyms ![]()  | 
                                                        
| Example 6 [WO2014169843] | 
Database Links ![]()  | 
                                                        |
| CAS Registry No. | 2739690-43-6 (source: WHO INN record) | 
| GtoPdb PubChem SID | 500839905 | 
| PubChem CID | 135210935 | 
| Search Google for chemical match using the InChIKey | RJFDJJABNSVLRB-UHFFFAOYSA-N | 
| Search Google for chemicals with the same backbone | RJFDJJABNSVLRB | 
| Search PubMed clinical trials | luvometinib | 
| Search PubMed titles | luvometinib | 
| Search PubMed titles/abstracts | luvometinib | 
| UniChem Compound Search for chemical match using the InChIKey | RJFDJJABNSVLRB-UHFFFAOYSA-N | 
| UniChem Connectivity Search for chemical match using the InChIKey | RJFDJJABNSVLRB-UHFFFAOYSA-N |